Martin C. Glass is co-chair of the firm’s Cross-Border Transactions Practice and is currently serving on our Management Committee. He counsels US and foreign companies in a wide array of transactional matters. He is recognized as a leading lawyer by Chambers USA, which states that “he is a technically strong lawyer with an ability to deliver practical advice in a clear and coherent manner”.

For over 20 years, Mr. Glass has focused on complex M&A and securities transactions. Domestic and foreign companies and their boards, as well as private equity funds, family offices, and investment banks, seek his assistance with structuring and negotiating public and private mergers, acquisitions, divestitures, SPAC transactions, public securities offerings, proxy contests, and other highly complex corporate transactions. Mr. Glass also regularly counsels clients on continuous reporting and corporate governance requirements under the US securities laws and the rules of the NYSE and NASDAQ. 

He has been named as a BTI Consulting Group Inc. "Client Service All-Star" based on the survey of general counsels of the Fortune 1000, an award that identifies attorneys that are "not just great—but head and shoulders above the rest as defined solely by clients." For several years running, Mr. Glass has been mentioned in Euromoney's IFLR1000 listing of the world's leading lawyers and recommended in The Legal 500 United States. He has also been named a Law360 "MVP." He is a member of the Committee on Mergers, Acquisitions and Proxy Contests of the New York City Bar Association.

Mr. Glass has experience in a broad range of industries, including life sciences, technology, mining, energy, and financial services.

Representative mergers and acquisitions engagements include the following:

  • Swiss-based Lonza Group Ltd. in its $5.5 billion acquisition of Capsugel S.A., a KKR + Co. L.P. portfolio company.
  • Shift Technologies, Inc. (Nasdaq: SFT) in its $700 million SPAC go-public transaction.
  • Zijin Mining Group Co. in its $1.25 billion acquisition of Nevsun Resources Ltd. (NYSE: NSU).
  • Chicago-based Cresco Labs, Inc. in its CAN$2.2 billion reverse takeover transaction and public listing on the Canadian Securities Exchange.
  • Snyder’s-Lance, Inc. (Nasdaq: LNCE) in its $1.8 billion acquisition of Diamond Foods, Inc. (Nasdaq: DMND).
  • Japan-based THK Co. in its $400 million acquisition of the linkage and suspension business of TRW Automotive Holdings Corp.
  • Papillion Resources Ltd. in its $570 million sale to B2Gold Corp.
  • Richmont Mines Inc. (NYSE: RIC) in its $770 million sale to Alamos Gold Inc. (NYSE: AGI).

Representative securities and finance engagements include the following:

  • Clementia Pharmaceuticals Inc. (Nasdaq: CMTA) in its $138 million initial public offering led by Morgan Stanley and Leerink Partners; its $50 million follow-on public offering and its $40 million at-the-market offering program.
  • Aurora Cannabis Inc. (NYSE: ACB) in its $345 million 5.5% convertible senior notes due 2024 offering led by BMO Capital Markets and Cowen.
  • StarTek, Inc. in connection with an equity infusion into the company by Amazon.com, Inc.
  • Cresco Labs, LLC in a US $100 million financing round and a subsequent CAN$120 million financing led by Canaccord Genuity and GMP Securities.
  • Lonza Group Ltd. in a $2.3 billion rights offering and in a $865 million common stock offering.
  • Stifel Nicolaus as lead underwriter for the initial public offering of Exa Corporation (Nasdaq: EXA).
  • Richmont Mines Inc. in its NYSE listing.
  • Theratechnologies Inc. in its Nasdaq listing.
  • Obagi Medical Products, Inc. in its $145 million follow-on public offering.
  • Tengion, Inc. a leader in the field of regenerative medicine, in its initial public offering.